Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Show more...
FAQ
Veracyte 今天的股價是多少?▼
12V.STU 目前價格為 €31.6 EUR,過去 24 小時上漲了 +12.5%。在圖表上更密切關注 Veracyte 股價表現。
Veracyte 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Veracyte 的股票以代號 12V.STU 進行交易。
Veracyte 的股價在上漲嗎?▼
12V.STU 股票較上週上漲 +16.82%,本月上漲 +13.67%,過去一年 Veracyte 上漲 +18.8%。
Veracyte 下一次財報日期是什麼時候?▼
Veracyte 將於 August 11, 2026 公布下一次財報。
Veracyte 上一季度的財報如何?▼
12V.STU 上一季度的財報為每股 0.44 EUR,預估為 0.28 EUR,帶來 +55.89% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
Veracyte 有多少名員工?▼
截至 May 06, 2026,公司共有 755 名員工。
Veracyte 位於哪個產業?▼
Veracyte從事於Health & Wellness產業。
Veracyte 何時完成拆股?▼
Veracyte 最近沒有進行任何拆股。
Veracyte 的總部在哪裡?▼
Veracyte 的總部位於 美國 的 South San Francisco。